Press Releases

• ABLi Therapeutics: Outcomes From Its Parkinson’s-related Biomarker Study Demonstrating Modification of Human Disease With Risvodetinib More
• Akebia Therapeutics: Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases More
• Bioxytran: Leverages Artificial Super Intelligence (ASI) to Design Broad-Spectrum Antiviral and Anti-Cancer Metastasis Drugs More
• BostonGene: Business Intelligence Group Names BostonGene Outstanding Organization and Double Winner in the 2026 Artificial Intelligence Excellence Awards More
• Decoy Therapeutics: Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMPACT Platform More
• Haemonetics: New Study Offers Additional Evidence for the VASCADE MVP XL System’s Effectiveness in Electrophysiology Procedures With Large Bore Sheaths More
• Healis Therapeutics: FDA Clears IND for Tyemvers, Enabling U.S. Neuropsychiatric Trials More
• Oblenio: First Patients Dosed in Innovative Phase 1a Trial of LBL-051 in Refractory Autoimmune Diseases More
• Rhythm Pharmaceuticals: Preliminary Data From Phase 2 Trial That Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity More
• Satellite Bio: FDA Clearance of IND Application for SB-101 for the Treatment of Urea Cycle Disorders (UCDs) Marking its Transition to a Clinical-Stage Biotechnology Company More
• Taysha Gene Therapies and Catalent: Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome More
• Zevra Therapeutics: Publication of Four-Year Real-World Data From U.S. Early Access Program Evaluating MIPLYFFA (arimoclomol) in Niemann-Pick Disease Type C (NPC) More

Financial News

• Akebia Therapeutics: Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) More
• Apnimed: Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares More
• Bruker: Second Quarter 2026 Financial Results More
• Candel Therapeutics: Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) More
• Cirrus Therapeutics: Strengthens Its Position as a Next-Generation Global Ocular Immunology Leader With Singapore Eye Research Institute (SERI) Collaboration and Additional Financing More
• CRISPR Therapeutics: Business Update and Second Quarter 2026 Financial Results More
• Curium: Definitive Agreement to Merge With Lantheus More More More* More*
• Damora Therapeutics: Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) More
• Dana-Farber Cancer Institute: Department of Pathology Awarded $2.875 Million Over Five Years From NCI More
• Dash Bio: Raises $30M Series A to Accelerate Drug Development Timelines More More*
• Dianthus Therapeutics: Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) More
• Keros Therapeutics: Second Quarter 2026 Financial Results More
• More on Ratio Therapeutics Raising $70 Million for Radiopharma Pipeline More*
• Obsidian Therapeutics: Completes Closing of Transaction With Galera Therapeutics and Previously Announced Private Placement of $350 Million More
• Odyssey Therapeutics: Second Quarter 2026 Financial Results and Provides Corporate Update More
• Revvity: Financial Results for the Second Quarter of 2026 More
• Rhythm Pharmaceuticals: Second Quarter 2026 Financial Results and Business Update More
• Stoke Therapeutics: Second Quarter 2026 Financial Results and Business Updates More
• TransMedics: Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) More
• UFP Technologies: Record Q2 Results More
• Vertex: Second Quarter 2026 Financial Results More More*
• Vor Bio: Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) More

Media/Misc Coverage

• A Rescue Model for Shelved Drug Candidates With Annette Bakker, Ph.D. and Andrew Lo, Ph.D. Podcast
  
• Big4Bio CEO Weekly Q&A: Todd Dickinson, President & CEO, Stellaromics More
• Cancer-Fighting Antibodies With a One-Two Punch Take Aim at Tumours More*
• Receptor.AI, Sethera Team Up on AI-Driven Peptide Discovery More* More
  
• Slone Partners: Premier Executive Search and Talent Advisory Firm More
  
• Subscribe to LifeSci Startup for Updates on US Startups More

Career Moves

• Cue Biopharma: Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission More
• Marengo: Nominates First Drug Candidate Under Strategic TriSTAR Collaboration with Ipsen and Welcomes Industry-Leading T-Cell Engager Expert, Saso Cemerski, Ph.D., to Accelerate Pipeline Expansion More
• OPPORTUNITY: Chief Scientific Officer, Manassas, VA More
• OPPORTUNITY: President, PA More
• OPPORTUNITY: Vice President, Global BD, Remote More
• Slone Partners: Places Amer Mirza, PhD, as Chief Scientific Officer at Prolynx More
• Slone Partners: The Convergence of MedTech and Digital Health - How New Hybrid Devices Are Reshaping Care Delivery and Leadership Profiles More

• Online Auction: Level Up Pharmaceuticals West Coast Laboratory Facility Closure Aug 3-6
  
• Biocom Seattle Summer Soirée Aug 5
• Biocom San Diego Summer Soirée Aug 6
• The Bioprocessing Summit 2026 Aug 10-13
• Biocom Peninsula Summer Soirée Aug 13
• The Matrix One West Coast MedTech Forum Aug 18-27
  
• Biocom East Bay Summer Soirée Aug 20
• Next Generation Dx Summit Aug 24-26
• HUBS West Sept 1-2
• Partnerships with Sites Summit Sept 14
• Charles River Biotech Symposium Sept 14-16
• Fierce Pharma Week Sept 14-17
• 16th Annual DPHARM Sept 15-16
• Biotech Week Boston 2026 Sept 22-25

Companies

Boston Sponsors